Biogen hematology news

Biogen will spin off its hemophilia business into a separate public company by early 2017. It plans to distribute shares in the still-unnamed company to Biogen stockholders. Biogen will not have an ownership stake

Read the full 349 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE